SCHEMBL845250

SCHEMBL845250

CSCC(=O)N1CCC[C@H]1C(=O)Nc1ccc(/C=C/c2ccc(NC(=O)[C@@H]3CCCN3C(=O)c3ccccn3)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 3/20 0.46
HCRTR2 O43614 3/20 0.46
DGAT1 O75907 4/20 0.43
PABPC1 P11940 1/20 0.43
ALDH1A1 P00352 3/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDM4E B2RXH2 2/20 0.41
GAA P10253 1/20 0.41
LMNA P02545 1/20 0.41
MAPK1 P28482 2/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
TP53BP1 Q12888 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL845048 0.91 DGAT1 (0.50) DGAT1PABPC1ALDH1A1CYP2C9CYP2C19
SCHEMBL845228 0.87 HCRTR1 (0.49) HCRTR1HCRTR2PABPC1ALDH1A1CYP2C9
SCHEMBL845591 0.86 HCRTR1 (0.49) HCRTR1HCRTR2PABPC1ALDH1A1CYP2C9
SCHEMBL845935 0.85 PABPC1 (0.44) DGAT1PABPC1ALDH1A1CYP2C9CYP2C19
SCHEMBL844963 0.84 DGAT1 (0.47) DGAT1PABPC1ALDH1A1CYP2C9CYP2C19
SCHEMBL845231 0.83 HCRTR1 (0.43) HCRTR1HCRTR2ALDH1A1CYP2C9CYP2C19
SCHEMBL845643 0.82 MAPK1 (0.50) DGAT1PABPC1ALDH1A1CYP2C9CYP2C19
SCHEMBL845195 0.80 HCRTR1 (0.46) HCRTR1HCRTR2PABPC1ALDH1A1CYP2C9
SCHEMBL13272381 0.80 PABPC1 (0.40) DGAT1PABPC1ALDH1A1CYP2C9CYP2C19
SCHEMBL13865067 0.79 HCRTR1 (0.62) HCRTR1HCRTR2PABPC1ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed